Paradoxical eczematous reaction to ixekizumab

Munera‐Campos, Mónica; Ballescá, F.; Richarz, Nina A.; Ferrándiz, Carlos; Carrascosa, J.M.

doi:10.1111/jdv.15156

Cited by 24 publications

(20 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been anecdotal case reports showing exacerbation of AD-like dermatitis after treatment with anti-IL17 antibody for psoriasis [57][58][59]. A 31-year-old man with severe psoriasis treated with ixekizumab presented with a one-month history of pruritic lesions [57]. The patient had no personal or family history of allergy, AD, or eczema.…”

Section: Other Biologics and Admentioning

confidence: 99%

See 1 more Smart Citation

The Role of Th17-Related Cytokines in Atopic Dermatitis

Sugaya

2020

IJMS

137

102

View full text Add to dashboard Cite

T helper-17 (Th17) cells, which mainly produce IL-17, are associated with development of various autoimmune diseases such as rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis, and psoriasis. IL-17 and related cytokines are therapeutic targets of these diseases. In atopic dermatitis (AD), Th2 cytokines such as IL-4 and IL-13 are regarded to be the main player of the disease; however, Th17 cytokines are also expressed in AD skin lesions. Expression of IL-22 rather than IL-17 is predominant in AD skin, which is contrary to cytokine expression in psoriasis skin. Relatively low IL-17 expression in AD skin can induce relatively low antimicrobial peptide expression, which may be a reason why bacterial infection is frequently seen in AD patients. Failure of clinical trials for investigating the efficacy of anti-IL-12/23 p40 in AD has suggested that IL-17 expressed in skin lesions should not be the main player but a bystander responding to barrier dysfunction.

show abstract

Section: Other Biologics and Admentioning

confidence: 99%

“…IL-17A Worsening of dermatitis [57][58][59] IL-12/23p40 No effect in clinical trial [55,56] IL-22 Effective for some patients [60,61] IL-4/13 Very effective [68]…”

Section: Clinical Response Referencesmentioning

confidence: 99%

The Role of Th17-Related Cytokines in Atopic Dermatitis

Sugaya

2020

IJMS

137

102

View full text Add to dashboard Cite

show abstract

“…However, paradoxical reactions to new biologic therapies have not been widely studied, so their therapeutic or prognostic implications and the precise etio-pathogenic and immunologic mechanisms behind them are not fully understood. A recent case of paradoxical eczematous reaction following ixekizumab therapy has been described, in which a switch to eczematous inflammatory phenotype secondary to decreased IL17 levels was hypothesized as a possible mechanism [5].…”

Section: Case Discussionmentioning

confidence: 99%

Paradoxical reversed plantar involvement during ixekizumab therapy for psoriasis

Martínez-Doménech,

García-Legaz-Martínez,

Magdaleno-Tapial

et al. 2019

Dermatology Online Journal

View full text Add to dashboard Cite

“…On the other hand, in recent months, a paradoxical eczematous reaction during treatment with ixekizumab49 and a report of atopic-like dermatitis after secukinumab injection50 have been reported in the literature. In our experience, we have observed similar cases in our daily practice.…”

Section: Brodalumab the Latest Approved Treatment In The Anti-il-17 mentioning

confidence: 99%

<p>Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date</p>

Galluzzo

D’Adamio

Massaro

et al. 2019

CCID

View full text Add to dashboard Cite

The IL-17/IL-23 axis is now understood to influence psoriasis, and the development of novel IL-17 inhibitor medications marks a sea change in the treatment of psoriasis. Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against IL-17RA. This article discusses the mechanism of action and the efficacy and safety profile of brodalumab presented in the literature. Brodalumab, the latest approved anti-IL-17-class medication, is the only one that exerts its effects on IL-17C as well as on IL-17A and IL-17F, blocking the shared IL-17 receptor A. In this sense, considering the recent evidence, brodalumab could have beneficial effects not only on psoriasis, but also on atopic dermatitis. It could also serve as a therapeutic alternative in patients who develop paradoxical eczematous reactions or atopic-like dermatitis during treatment with other anti-IL-17A (secukinumab, ixekizumab).

show abstract

Paradoxical eczematous reaction to ixekizumab

Cited by 24 publications

References 14 publications

The Role of Th17-Related Cytokines in Atopic Dermatitis

The Role of Th17-Related Cytokines in Atopic Dermatitis

Paradoxical reversed plantar involvement during ixekizumab therapy for psoriasis

<p>Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date</p>

Contact Info

Product

Resources

About